Source: AREVA Med & reported by http://globenewswire.com/
HOUSTON and BETHESDA, Md., May 18, 2015 (GLOBE NEWSWIRE) -- RadioMedix, a clinical phase biotechnology company focused in the development of radiopharmaceuticals for targeted diagnosis and therapy of cancer, and AREVA Med, the AREVA medical subsidiary developing innovative therapies to fight cancer, announced today that they have entered into an agreement to co-develop a novel treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212 (212Pb).
Under the terms of the agreement, RadioMedix and AREVA Med will assess the efficacy of combining somatostatin analogs' neuroendocrine tumor targeting capabilities with the cell-killing potential of AREVA Med's lead-212 radionuclide. This approach, known as "Peptide Receptor Radio Therapy" (PRRT), has already been tested with beta emitting radioisotopes. The alpha emitters from lead-212's decay chain are expected to deliver superior clinical benefits to patients suffering from metastasized NETs where conventional methods, such as surgery or chemotherapy, have been ineffective.
"Development of the next generation of PRRT agents with Alpha emitters for targeted treatment of metastatic or inoperable neuroendocrine cancers is a natural next step in evolution of this treatment platform. Alpha PRRT will bring us closer to a 'cure' of this cancer and will provide significant new hope to our patients fighting this disease. Collaboration with AREVA Med will allow us to have a sustainable source of Alpha emitter 212Pb to achieve this goal," said Ebrahim S. Delpassand, M.D. RadioMedix Chairman and CEO.
- See more at: http://globenewswire.com/news-release/2015/05/18/736758/10134316/en/AREVA-Med-and-RadioMedix-Partner-to-Develop-New-Treatment-Against-Neuroendocrine-Tumors.html#sthash.JP3U7jPu.dpuf